Advertisement

Topics

Valeant: A Real Bounceback or a Dead Cat?

20:30 EST 15 Dec 2017 | Topix

Shares of Valeant Pharmaceuticals International are higher on Friday, recovering from a downgrade from JPMorgan yesterday, but investors shouldn't get too comfortable, warns Mizuho Securities . Analyst Irina Koffler reiterated an Underperform rating on the stock today, although she did raise he price target from $7 to $10.

Original Article: Valeant: A Real Bounceback or a Dead Cat?

NEXT ARTICLE

More From BioPortfolio on "Valeant: A Real Bounceback or a Dead Cat?"

Advertisement
Quick Search
Advertisement
Advertisement